SynthesisFrontiers in immunology2019
Anti-p200 Pemphigoid: A Systematic Review.
Synthesis in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review.Frontiers in immunology · 2022Pooled it
- Incidence of P200 pemphigoid: A nationwide study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.Biomolecules · 2026Article
- Anti-p200 pemphigoid with autoantibodies targeting laminin beta-4 and clinical response to methotrexate.JAAD case reports · 2025Article
- Antibodies to Laminin β4 in Pemphigoid Diseases: Clinical-Laboratory Experience of a Single Central European Reference Centre.Antibodies (Basel, Switzerland) · 2025Article
- A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.Dermatology and therapy · 2025Review
- Pemphigoid with Autoantibodies against p200 and all Subunits of Laminin 332 Associated with Drug Eruption Caused by Piperacillin/tazobactam.Acta dermato-venereologica · 2025Article
- Pemphigoid disease model systems for clinical translation.Frontiers in immunology · 2025Review
- Anti-LGI1 encephalitis and co-existence of MOG-IgG: a case report and literature review.Frontiers in human neuroscience · 2025Article
- Anti-p200 Pemphigoid Mimicking Acquired Reactive Perforating Collagenosis.Acta dermato-venereologica · 2024Article
- State-of-the-art diagnosis of autoimmune blistering diseases.Frontiers in immunology · 2024Review
- [Pemphigoid diseases in older adults].Dermatologie (Heidelberg, Germany) · 2023Review
- Case Report of a Novel Association between Anti-p200 Pemphigoid and Acquired Haemophilia A.Annals of dermatology · 2023Article
- Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid.Frontiers in immunology · 2023Review
- The Intriguing Links between Psoriasis and Bullous Pemphigoid.Journal of clinical medicine · 2022Review
- [Rare variants of pemphigoid diseases].Dermatologie (Heidelberg, Germany) · 2022Review
- Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.American journal of clinical dermatology · 2022Review
- Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.Journal of clinical medicine · 2022Review
- Anti-p200 pemphigoid mimicking erythema multiforme.JAAD case reports · 2022Article
- A case of anti-laminin gamma-1 (p200) pemphigoid with bullous lesions on the lips, hands and feet showing antibodies to desmoglein 1.Skin health and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The many clinical aspects of anti-p200 pemphigoid are not well-characterized. We aimed to analyze and correlate known existing data on the epidemiological, clinical, histological, and immunological features of anti-p200 pemphigoid. We performed a review using Medline, Embase, and Web of Science databases (1900-2018). Case reports and series of patients were included. A total of 68 eligible studies that comprised 113 anti-p200 pemphigoid patients were included in the qualitative analysis, where there was a mean age of onset of 65.5 years. All patients presented with bullae/vesicles, and 54.3% had urticarial plaques. A similarity to bullous pemphigoid was reported in 66.1% of cases, but palmoplantar (51.4%), cephalic (40.3%), and mucosal (38.5%) involvement, besides frequent development of scars/milia (15.7%), were reported. Autoantibodies against recombinant laminin γ1 were detected in the sera of 73.1% of patients. Psoriasis was present in 28.3% of anti-p200 pemphigoid patients, particularly among Japanese patients (56.4%). The incidence of pustular psoriasis in this subgroup, was significantly greater than in the normal population. In conclusion, the diagnosis of anti-p200 pemphigoid may be suspected when a subepidermal autoimmune blistering disease develops in a younger age group, along with significant acral and cephalic distribution and mucosal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.